Chaki, Shigeyuki

Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression

Koike, H., Iijima, M., & Chaki, S. (2011) · Behavioural Brain Research

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 346

MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity

Chaki, S., Yoshikawa, R., Hirota, S., Shimazaki, T., Maeda, M., Kawashima, N., Yoshimizu, T., Yasuhara, A., Sakagami, K., Okuyama, S., et al. (2004) · Neuropharmacology

Neuroscience and Neuropharmacology ResearchTreatment of Major Depression

Cited by 254

Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine

Fukumoto, K., Toki, H., Iijima, M., Hashihayata, T., Yamaguchi, J.-I., Hashimoto, K., & Chaki, S. (2017) · The Journal of Pharmacology and Experimental Therapeutics

Treatment of Major DepressionTryptophan and brain disorders

Cited by 252

Neurochemistry of the nucleus accumbens and its relevance to depression and antidepressant action in rodents

Shirayama, Y., & Chaki, S. (2006) · Current Neuropharmacology

Neurotransmitter Receptor Influence on BehaviorTreatment of Major Depression

Cited by 225

The Antidepressant Effects of an mGlu2/3 Receptor Antagonist and Ketamine Require AMPA Receptor Stimulation in the mPFC and Subsequent Activation of the 5-HT Neurons in the DRN

Fukumoto, K., Iijima, M., & Chaki, S. (2016) · Neuropsychopharmacology

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 174

Mood disorders: Regulation by metabotropic glutamate receptors

Pilc, A., Chaki, S., Nowak, G., & Witkin, J. M. (2008) · Biochemical Pharmacology

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 163

Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists

Koike, H., Iijima, M., & Chaki, S. (2011) · Neuropharmacology

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 114

(2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice

Yamaguchi, J.-I., Toki, H., Qu, Y., Yang, C., Koike, H., Hashimoto, K., Mizuno-Yasuhira, A., & Chaki, S. (2018) · Neuropsychopharmacology

Treatment of Major DepressionTryptophan and brain disorders

Cited by 105

mGlu2/3 Receptor Antagonists as Novel Antidepressants

Chaki, S. (2017) · Trends in Pharmacological Sciences

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 73

Vasopressin V1B receptor antagonists as potential antidepressants

Chaki, S. (2021) · International Journal of Neuropsychopharmacology

Stress Responses and CortisolTreatment of Major Depression

Cited by 34

Stimulation of postsynapse adrenergic α2A receptor improves attention/cognition performance in an animal model of attention deficit hyperactivity disorder

Kawaura, K., Karasawa, J.-I., Chaki, S., & Hikichi, H. (2014) · Behavioural Brain Research

Attention Deficit Hyperactivity DisorderNeurotransmitter Receptor Influence on Behavior

Cited by 29

The selective metabotropic glutamate 2/3 receptor agonist MGS0028 reverses isolation rearing-induced abnormal behaviors in mice

Ago, Y., Araki, R., Yano, K., Kawasaki, T., Chaki, S., Nakazato, A., Onoe, H., Hashimoto, H., Baba, A., Takuma, K., et al. (2012) · Journal of Pharmacological Sciences

Neuroscience and Neuropharmacology ResearchSchizophrenia research and treatment

Cited by 29

Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study

Kamiya, M., Sabia, H. D., Marella, J., Fava, M., Nemeroff, C. B., Umeuchi, H., Iijima, M., Chaki, S., & Nishino, I. (2020) · Journal of Psychiatric Research

Treatment of Major DepressionStress Responses and Cortisol

Cited by 28

Evaluation of the Safety, Tolerability, and Pharmacokinetic Profiles of TP0473292 (TS-161), A Prodrug of a Novel Orthosteric mGlu2/3 Receptor Antagonist TP0178894, in Healthy Subjects and Its Antidepressant-Like Effects in Rodents

Watanabe, M., Marcy, B., Hiroki, A., Watase, H., Kinoshita, K., Iijima, M., Marumo, T., Zarate, C. A., & Chaki, S. (2022) · International Journal of Neuropsychopharmacology

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 22